Autolus Therapeutics (NASDAQ:AUTL) Sets New 52-Week Low – Here’s What Happened

Autolus Therapeutics plc (NASDAQ:AUTL) shares reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $3.05 and last traded at $3.09, with a volume of 998117 shares changing hands. The stock had previously closed at $3.29.

Analyst Ratings Changes

Separately, Needham & Company LLC restated a “buy” rating and issued a $9.00 target price on shares of Autolus Therapeutics in a report on Monday.

Autolus Therapeutics Trading Down 8.5 %

The firm has a market capitalization of $800.94 million, a price-to-earnings ratio of -2.64 and a beta of 2.04. The business has a 50-day moving average of $3.95 and a two-hundred day moving average of $4.00. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the previous year, the company posted ($0.26) EPS. Research analysts predict that Autolus Therapeutics plc will post -0.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AUTL. Renaissance Technologies LLC grew its holdings in Autolus Therapeutics by 253.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,145,056 shares of the company’s stock worth $3,985,000 after acquiring an additional 821,156 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Autolus Therapeutics by 82.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after buying an additional 2,487,778 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Autolus Therapeutics by 113.7% during the 2nd quarter. Millennium Management LLC now owns 813,031 shares of the company’s stock worth $2,829,000 after buying an additional 432,503 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Autolus Therapeutics by 2,603.8% in the 1st quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company’s stock valued at $736,000 after purchasing an additional 111,131 shares during the last quarter. Finally, Affinity Asset Advisors LLC lifted its stake in Autolus Therapeutics by 27.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock valued at $14,964,000 after purchasing an additional 925,000 shares during the last quarter. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.